Wikipedia -WSS

Wikipedia

author：Wikipedia 2025-10-02 12:41:52 - browse：46443

Daphne Koller -- biotech coverage from STAT — Daphne Koller, early biotech AI entrant Insitro's founder, CEO and board member. Courtesy Jerrick Mitra/Insitro

New artificial intelligence technologies made headlines last year for their ability to do everything from generating fake musical duets to understanding how proteins fold. But in biotech, one of the most well-funded AI players has been quiet.

Insitro, a South San Francisco firm, was founded in 2018 by Daphne Koller, who had previously been a Stanford professor, a 2004 MacArthur “genius” grant recipient, and the co-founder and co-CEO of the online course company Coursera. It raised more than $643 million in venture capital, according to PitchBook, from investors including T. Rowe Price, ARCH Venture Partners, and Casdin Capital. The company now has more than 260 employees spread out over 107,000 square feet of laboratory and office space.

But what exactly is Koller building?

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： See how much Covid

WSS

UnitedHealth’s Optum accused of antitrust violations in California

UnitedHealth’s Optum accused of antitrust violations in California

Kaiser's Risant Health gobbled up Geisinger. Who is next?

CDC director unscathed in first congressional testimony

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Shifting the focus from loneliness to social health

Wikipedia

Wikipedia

focus

Peter Hotez and the public health issue of online harassment

FDA's Pazdur wants cancer trials to range beyond China alone

Psychedelics group wrestles with new pharma identity

Rep. Raul Ruiz on the physician shortage and more

Walensky prepares to leave CDC — and Congress — behind

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Bright Health sells Medicare Advantage business to Molina

ASCO: AstraZeneca says CAR

23andMe had bad news about my health. I wish a person had delivered it

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

focus

What to do when lifesaving products contribute to climate change

With clinical trial data readouts, here's how to spot spin

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

ASCO: Palliative care found as helpful given virtually as in person

Diagnostic tests are hitting their mathematical limits

Letters to First Opinion on caregivers, digital health, and more

focus

knowledge

leisure time

focus